![](https://investorshub.advfn.com/uicon/822788.png?cb=1664635735)
Monday, December 11, 2023 3:10:18 PM
I hope you’ve been well. Thanks for reposting your opinion again about the ECA, but your post is bs as per usual.
Doctors Liau and Ashkan know how to run a clinical study.
You are never going to see the FDA or MHRA allow trial participants to be used as lab rats.
The crossover design was required to recruit and retain participants. Who would want to join a GBM study without crossover or remain in a placebo group after developing progressive disease without having the option of receiving an efficacious treatment?
![](http://investorshub.advfn.com/uimage/uploads/2023/11/5/hw[spIMG_6666.gif)
Conclusion: The P3 was exemplary—clinically appropriate and compassionate.
![](http://investorshub.advfn.com/uimage/uploads/2022/11/7/kiejvEE4F17D4-6311-4F70-9901-74305B933A38.jpeg)
Skip to timestamp 8:01. Dr. Liau again confirms that the crossover was mandated by the FDA.
https://edhub.ama-assn.org/jn-learning/audio-player/18738384
![](http://investorshub.advfn.com/uimage/uploads/2023/11/5/cszulIMG_6665.jpeg)
![](http://investorshub.advfn.com/uimage/uploads/2023/11/4/eceulIMG_6660.jpeg)
https://www.raps.org/news-and-articles/news-articles/2023/8/fda-finalizes-guidance-on-real-world-evidence-in-d
![](http://investorshub.advfn.com/uimage/uploads/2023/11/3/ctwdpIMG_6659.jpeg)
https://www.raps.org/News-and-Articles/News-Articles/2023/9/FDA%E2%80%99s-Califf-Expect-to-see-more-RWE-based-regulato
https://www.fda.gov/media/171667/download
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
Professor Ashkan is a careful and precise brain surgeon—listen to his words.
Skip to timestamp 13:00 of the ASCO video to hear about the ECA and the SAP.
https://www.kch.nhs.uk/news/kings-team-wins-professional-excellence-award/
![](http://investorshub.advfn.com/uimage/uploads/2022/11/14/qrzrqD56CD970-588F-4C46-8890-BD4A3A215781.jpeg)
![](http://investorshub.advfn.com/uimage/uploads/2022/11/14/mskxr446F43F4-17A0-4201-B24B-6D689E81B042.jpeg)
Explore Professor Keyoumars Ashkan's passion for neurosurgery and his love for @KingsCollegeNHS below as part of their #BrilliantPeople series🧠👇@KingsNeuro @KingsIoPPN https://t.co/yGKt2681Ie
— King's College London (@KingsCollegeLon) May 25, 2022
The clinical data in total supporting the DCVax-L platform technology include data beyond the trial with the ECA, and the ECA included over a thousand well-matched contemporaneous patients.
The P3 data were peer reviewed by independent physicians and qualified statisticians—refer to JAMA Oncology.
Safety and efficacy data have been gathered from various clinical settings that include both external controls and placebo controls. DCVax-L has been studied as a monotherapy and in combination with other agents.
If you prefer a randomized placebo design, then you’ll love the pembrolizumab PD1 blockade combo study that is ongoing at UCLA today. The study has a placebo design and the placebo participants are receiving DCVax-L as the best available therapy for rGBM.
The interim PD1 combo data are brilliant, and the trial is significant for a number of reasons relating to FDA guidelines and NIH peer-reviewed grant funding.
https://clinicaltrials.gov/ct2/show/NCT04201873
In the combo trial, patients who receive DCVax-L + placebo are being compared to patients who receive DCVax-L + pembrolizumab.
The control arm is receiving DCVax-L. While DCVax-L is not the current SOC, it is highly significant and notable that DCVax-L is being permitted to fill the role of SOC as the best available therapy within this combo study for rGBM. The combo trial also follows the P3 in sequence which in itself validates the findings of the P3 study—the placebo group in the PD1 study would not be receiving DCVax-L today if the preceding P3 trial had not produced reliable evidence of efficacy.
The U.S. NIH has supported the DCVax-L platform for years, and the NIH renewed its support in 2022 to continue to fund the development of this technology and to fund research into combination therapies.
NIH-funded DCVax-L research is ongoing at UCLA today.
NIH grants are peer-reviewed and the research that NIH funds is highly scrutinized in advance of the award and also intermittently for the term of the various research projects.
https://www.bentley.edu/news/new-study-shows-nih-investment-new-drug-approvals-comparable-investment-pharmaceutical
https://www.bentley.edu/news/nih-funded-research-related-every-new-cancer-drug-approved-2010-2016
https://ashpublications.org/ashclinicalnews/news/3819/NIH-Funding-Tied-to-FDA-Approval-of-210-Drugs
![](http://investorshub.advfn.com/uimage/uploads/2023/10/21/gkzosIMG_6566.jpeg)
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers
https://www.uclahealth.org/news/brain-cancer-discovery-clinical-trials
https://www.uclahealth.org/news/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020
https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter
https://finance.yahoo.com/news/northwest-biotherapeutics-announces-dr-linda-140000962.html
![Bullish](/static/images/ih2-bull.png)
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM